Dec 3 (Reuters) - AstraZeneca has signed a deal worth up to $247 million with U.S. firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday. (Reporting by Shivani Tanna in Bengaluru; Editing by William Mallard)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,332 GBX | +0.55% | +1.33% | +16.34% |
05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,332 GBX | +0.55% | +1.33% | 238B | ||
5.14 USD | +4.05% | +3.21% | 559M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.34% | 238B | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B | |
-2.12% | 160B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca ties up with AI biologics company to develop cancer drug - FT